| 1. | | Recruiting | Epoetin alfa in Treating Cancer-Related Anemia in Patients With Non-Myeloid Cancer Who Are Not Currently Receiving Chemotherapy or Radiation Therapy
Conditions: adult solid tumor; Anemia; Leukemia; Lymphoma; plasma cell neoplasm |
| 2. | | Recruiting | 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Conditions: chronic myeloproliferative disorders; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm |
| 3. | | Not yet recruiting | Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Conditions: acute leukemia; atypical chronic myeloid leukemia; chronic leukemia; myelodysplastic and myeloproliferative disease; Non-Hodgkin's Lymphoma; ... |
| 4. | | Recruiting | T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
Conditions: chronic myeloproliferative disorders; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm |
| 5. | | Recruiting | Sirolimus in Preventing Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Conditions: chronic myeloproliferative disorders; Graft Versus Host Disease; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; ... |
| 6. | | Recruiting | Total-Body Irradiation With Or Without Fludarabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
Conditions: childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; plasma cell neoplasm |
| 7. | | Recruiting | Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
Conditions: childhood Hodgkin's lymphoma; chronic myeloproliferative disorders; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; ... |
| 8. | | Recruiting | Donor Stem Cell Transplantation in Treating Patients With Relapsed Hematologic Cancer
Conditions: childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; ... |
| 9. | | Recruiting | Combining Chemotherapy, Tacrolimus, Mycophenolate Mofetil, and Radiation Therapy with Donor Bone Marrow Transplantation in Treating Patients with Hematologic Cancer
Conditions: childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; ... |
| 10. | | Recruiting | Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Conditions: Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm |
| 11. | | Recruiting | Combination Chemotherapy Plus Alemtuzumab Followed by Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Conditions: childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; ... |
| 12. | | Recruiting | MS-275 in Treating Patients With Hematologic Cancer
Conditions: acute leukemia; atypical chronic myeloid leukemia; chronic leukemia; myelodysplastic and myeloproliferative disease; plasma cell neoplasm |
| 13. | | Recruiting | Combination Chemotherapy Followed by Donor Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Genetic Disorders
Conditions: childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; plasma cell neoplasm |
| 14. | | Recruiting | Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Conditions: childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; ... |
| 15. | | Recruiting | Bone Marrow Transplantation in Treating Patients With Hematologic Cancers
Conditions: acute leukemia; atypical chronic myeloid leukemia; chronic leukemia; chronic myeloproliferative disorders; ... |
| 16. | | Recruiting | Donor Bone Marrow Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
Conditions: acute leukemia; atypical chronic myeloid leukemia; chronic leukemia; chronic myeloproliferative disorders; ... |
| 17. | | Recruiting | High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Conditions: childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; ... |
| 18. | | Recruiting | Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation
Conditions: adult Hodgkin's lymphoma; adult non-Hodgkin's lymphoma; Anxiety Disorder; childhood acute myeloid leukemia and other myeloid malignancies; ... |
| 19. | | Recruiting | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
| 20. | | Recruiting | CCI-779 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
| 21. | | Recruiting | Tandem Autologous Stem Cell Transplantation With or Without Maintenance Therapy After the Second Transplantation Compared With Autologous Stem Cell Transplantation Followed By Matched Sibling Allogeneic Stem Cell Transplantation in Patients With Stage II or Stage III Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
| 22. | | Recruiting | FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
| 23. | | Recruiting | Stem Cell Transplantation in Treating Patients With Previously-Treated Multiple Myeloma
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
| 24. | | Recruiting | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
Conditions: refractory plasma cell neoplasm; stage III multiple myeloma; unspecified adult solid tumor, protocol specific |
| 25. | | Recruiting | Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 26. | | Recruiting | Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 27. | | Recruiting | Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 28. | | Recruiting | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis |
| 29. | | Recruiting | Antineoplaston Therapy in Treating Patients With Multiple Myeloma
Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 30. | | Recruiting | High-Dose Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Amyloidosis
Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis |
| 31. | | Recruiting | Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Conditions: Hematologic Disease; Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome; Myeloproliferative Disorder |
| 32. | | Recruiting | Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Conditions: adult non-Hodgkin's lymphoma; indolent or aggressive adult non-Hodgkin's lymphoma; refractory plasma cell neoplasm |
| 33. | | Recruiting | Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer
Conditions: adult solid tumor; fever, sweats, and hot flashes; hematopoietic and lymphoid cancer; Infection; Neutropenia |
| 34. | | Recruiting | Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II
Condition: Multiple Myeloma |
| 35. | | Recruiting | A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
Condition: Multiple Myeloma |
| 36. | | Not yet recruiting | Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination with DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma
Condition: Multiple Myeloma |
| 37. | | Recruiting | Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant
Condition: Multiple Myeloma |
| 38. | | Recruiting | Bortezomib and Liposomal Doxorubicin in Treating Patients With Multiple Myeloma
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 39. | | Recruiting | Study of Oral SCIO-469 in Relapsed, Refractory Patients with Multiple Myeloma
Condition: Multiple Myeloma |
| 40. | | Not yet recruiting | Melphalan and Amifostine Followed By Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Conditions: Drug Toxicity; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 41. | | Recruiting | Safety and Efficacy of Atiprimod for Patients with Refractory Multiple Myeloma
Condition: Multiple Myeloma |
| 42. | | Recruiting | Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma |
| 43. | | Recruiting | Study Comparing Skeletal Targeted Radiotherapy (STR) plus Melphalan to Melphalan Alone, with Stem Cell Transplant in Multiple Myeloma
Condition: Multiple Myeloma |
| 44. | | Recruiting | Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally
Condition: Multiple Myeloma |
| 45. | | Recruiting | Study of Combination PS-341 and Thalidomide in Multiple Myeloma
Condition: Multiple Myeloma |
| 46. | | Recruiting | Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide
Condition: Multiple Myeloma |
| 47. | | Recruiting | Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide
Condition: Multiple Myeloma |
| 48. | | Recruiting | UARK 2003-33, Total Therapy III
Condition: Multiple Myeloma |
| 49. | | Recruiting | Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients with Relapsed Multiple Myeloma
Condition: Multiple Myeloma |
| 50. | | Recruiting | Study of SGN-40 (anti-huCD40 mAb) in Patients with Refractory or Recurrent Multiple Myeloma
Condition: Multiple Myeloma |
